Study of Pembrolizumab With Bendamustine in Hodgkin Lymphoma

This is a phase 2 open-label study to test the safety and effectiveness of combining pembrolizumab and bendamustine in patients with relapsed (cancer that has come back or started getting worse) or refractory (cancer that is not responding or has stopped responding to treatment) Hodgkin lymphoma.

Trial Details

NCT ID

NCT04510636

Phase

PHASE2

Sponsor

University Health Network, Toronto

Status

RECRUITING

Cancer Type

Lymphoma

Interventions

Pembrolizumab
Bendamustine Hydrochloride

Locations (sample)

Toronto, Ontario, Canada|43.70643,-79.39864

Key Eligibility Criteria

Be willing and able to provide written informed consent for the trial and adhere to trial procedures.
Be age ≥18 years at the time of signing informed consent.
Have histologically confirmed relapsed (disease progression after most recent therapy) or refractory (failure to achieve CR or PR to most recent th…
Must have received at least standard first line chemotherapy for classical Hodgkin Lymphoma, containing an anthracycline, i.e. ABVD or BEACOPP.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →